dc.contributor.author | Brunt, AM | |
dc.contributor.author | Haviland, JS | |
dc.contributor.author | Sydenham, M | |
dc.contributor.author | Agrawal, RK | |
dc.contributor.author | Algurafi, H | |
dc.contributor.author | Alhasso, A | |
dc.contributor.author | Barrett-Lee, P | |
dc.contributor.author | Bliss, P | |
dc.contributor.author | Bloomfield, D | |
dc.contributor.author | Bowen, J | |
dc.contributor.author | Donovan, E | |
dc.contributor.author | Goodman, A | |
dc.contributor.author | Harnett, A | |
dc.contributor.author | Hogg, M | |
dc.contributor.author | Kumar, S | |
dc.contributor.author | Passant, H | |
dc.contributor.author | Quigley, M | |
dc.contributor.author | Sherwin, L | |
dc.contributor.author | Stewart, A | |
dc.contributor.author | Syndikus, I | |
dc.contributor.author | Tremlett, J | |
dc.contributor.author | Tsang, Y | |
dc.contributor.author | Venables, K | |
dc.contributor.author | Wheatley, D | |
dc.contributor.author | Bliss, JM | |
dc.contributor.author | Yarnold, JR | |
dc.date.accessioned | 2020-04-02T10:21:50Z | |
dc.date.issued | 2020-10-01 | |
dc.identifier.citation | Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2020, 38 (28), pp. 3261 - 3272 | |
dc.identifier.issn | 0732-183X | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/3569 | |
dc.identifier.eissn | 1527-7755 | |
dc.identifier.doi | 10.1200/jco.19.02750 | |
dc.description.abstract | PURPOSE: Previous studies of hypofractionated adjuvant whole-breast radiotherapy for early breast cancer established a 15- or 16-fraction (fr) regimen as standard. The FAST Trial (CRUKE/04/015) evaluated normal tissue effects (NTE) and disease outcomes after 5-fr regimens. Ten-year results are presented. METHODS: Women ≥ 50 years of age with low-risk invasive breast carcinoma (pT1-2 pN0) were randomly assigned to 50 Gy/25 fr (5 weeks) or 30 or 28.5 Gy in 5 once-weekly fr of 6.0 or 5.7 Gy. The primary end point was change in photographic breast appearance at 2 and 5 years; secondary end points were physician assessments of NTE and local tumor control. Odds ratios (ORs) from longitudinal analyses compared regimens. RESULTS: A total of 915 women were recruited from 18 UK centers (2004-2007). Five-year photographs were available for 615/862 (71%) eligible patients. ORs for change in photographic breast appearance were 1.64 (95% CI, 1.08 to 2.49; P = .019) for 30 Gy and 1.10 (95% CI, 0.70 to 1.71; P = .686) for 28.5 Gy versus 50 Gy. α/β estimate for photographic end point was 2.7 Gy (95% CI, 1.5 to 3.9 Gy), giving a 5-fr schedule of 28 Gy (95% CI, 26 to 30 Gy) estimated to be isoeffective with 50 Gy/25 fr. ORs for any moderate/marked physician-assessed breast NTE (shrinkage, induration, telangiectasia, edema) were 2.12 (95% CI, 1.55 to 2.89; P < .001) for 30 Gy and 1.22 (95% CI, 0.87 to 1.72; P = .248) for 28.5 Gy versus 50 Gy. With 9.9 years median follow-up, 11 ipsilateral breast cancer events (50 Gy: 3; 30 Gy: 4; 28.5 Gy: 4) and 96 deaths (50 Gy: 30; 30 Gy: 33; 28.5 Gy: 33) have occurred. CONCLUSION: At 10 years, there was no significant difference in NTE rates after 28.5 Gy/5 fr compared with 50 Gy/25 fr, but NTE were higher after 30 Gy/5 fr. Results confirm the published 3-year findings that a once-weekly 5-fr schedule of whole-breast radiotherapy can be identified that appears to be radiobiologically comparable for NTE to a conventionally fractionated regimen. | |
dc.format | Print-Electronic | |
dc.format.extent | 3261 - 3272 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | AMER SOC CLINICAL ONCOLOGY | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | |
dc.title | Ten-Year Results of FAST: A Randomized Controlled Trial of 5-Fraction Whole-Breast Radiotherapy for Early Breast Cancer. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2020-03-30 | |
rioxxterms.versionofrecord | 10.1200/jco.19.02750 | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by/4.0 | |
rioxxterms.licenseref.startdate | 2020-10 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | |
pubs.issue | 28 | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Trials & Statistics Unit | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Trials & Statistics Unit | |
pubs.publication-status | Published | |
pubs.volume | 38 | |
pubs.embargo.terms | Not known | |
icr.researchteam | Clinical Trials & Statistics Unit | |
dc.contributor.icrauthor | Haviland, Joanne | |
dc.contributor.icrauthor | Sydenham, Mark | |
dc.contributor.icrauthor | Bliss, Judith | |
dc.contributor.icrauthor | Yarnold, John | |